139 related articles for article (PubMed ID: 33541270)
1. Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England.
Persson MSM; Harman KE; Thomas KS; Chalmers JR; Vinogradova Y; Langan SM; Hippisley-Cox J; Gran S
BMC Med Res Methodol; 2021 Feb; 21(1):22. PubMed ID: 33541270
[TBL] [Abstract][Full Text] [Related]
2. Validation study of bullous pemphigoid and pemphigus vulgaris recording in routinely collected electronic primary healthcare records in England.
Persson MSM; Harman KE; Vinogradova Y; Langan SM; Hippisley-Cox J; Thomas KS; Gran S
BMJ Open; 2020 Jul; 10(7):e035934. PubMed ID: 32665386
[TBL] [Abstract][Full Text] [Related]
3. Long-term oral prednisolone exposure in primary care for bullous pemphigoid: population-based study.
Persson MS; Harman KE; Thomas KS; Chalmers JR; Vinogradova Y; Langan SM; Hippisley-Cox J; Gran S
Br J Gen Pract; 2021 Dec; 71(713):e904-e911. PubMed ID: 34607796
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Mason J; Childs M; Whitham D; Harman K; Chapman A; Walton S; Schmidt E; Godec TR; Nunn AJ; Williams HC
Health Technol Assess; 2017 Mar; 21(10):1-90. PubMed ID: 28406394
[TBL] [Abstract][Full Text] [Related]
5. The AMBER care bundle for hospital inpatients with uncertain recovery nearing the end of life: the ImproveCare feasibility cluster RCT.
Koffman J; Yorganci E; Murtagh F; Yi D; Gao W; Barclay S; Pickles A; Higginson I; Johnson H; Wilson R; Bailey S; Ewart C; Evans C
Health Technol Assess; 2019 Oct; 23(55):1-150. PubMed ID: 31594555
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.
Chalmers JR; Wojnarowska F; Kirtschig G; Nunn AJ; Bratton DJ; Mason J; Foster KA; Whitham D; Williams HC;
Br J Dermatol; 2015 Jul; 173(1):227-34. PubMed ID: 25683592
[TBL] [Abstract][Full Text] [Related]
7. [Bullous scabies and scabies-triggered bullous pemphigoid].
Bornhövd E; Partscht K; Flaig MJ; Messer G
Hautarzt; 2001 Jan; 52(1):56-61. PubMed ID: 11220241
[TBL] [Abstract][Full Text] [Related]
8. Bullous pemphigoid in an infant.
Cowen P
Australas J Dermatol; 1995 May; 36(2):97-8. PubMed ID: 7646398
[TBL] [Abstract][Full Text] [Related]
9. Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT.
Thomas SA; Drummond AE; Lincoln NB; Palmer RL; das Nair R; Latimer NR; Hackney GL; Mandefield L; Walters SJ; Hatton RD; Cooper CL; Chater TF; England TJ; Callaghan P; Coates E; Sutherland KE; Eshtan SJ; Topcu G
Health Technol Assess; 2019 Sep; 23(47):1-176. PubMed ID: 31524133
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
[TBL] [Abstract][Full Text] [Related]
11. Current Clinical Trials in Pemphigus and Pemphigoid.
Izumi K; Bieber K; Ludwig RJ
Front Immunol; 2019; 10():978. PubMed ID: 31130959
[TBL] [Abstract][Full Text] [Related]
12. Interventions for bullous pemphigoid.
Khumalo N; Kirtschig G; Middleton P; Hollis S; Wojnarowska F; Murrell D
Cochrane Database Syst Rev; 2005 Jul; (3):CD002292. PubMed ID: 16034874
[TBL] [Abstract][Full Text] [Related]
13. Interventions for bullous pemphigoid.
Khumalo N; Kirtschig G; Middleton P; Hollis S; Wojnarowska F; Murrell D
Cochrane Database Syst Rev; 2003; (3):CD002292. PubMed ID: 12917929
[TBL] [Abstract][Full Text] [Related]
14. Bullous pemphigoid and antecedent neurological diseases: An association with dementia.
Yu Phuan CZ; Yew YW; Tey HL
Indian J Dermatol Venereol Leprol; 2017; 83(4):457-461. PubMed ID: 28584223
[TBL] [Abstract][Full Text] [Related]
15. Bullous pemphigoid in adolescence.
Patsatsi A; Kyriakou A; Werth VP
Pediatr Dermatol; 2019 Mar; 36(2):184-188. PubMed ID: 30569520
[TBL] [Abstract][Full Text] [Related]
16. Comparison of dementia recorded in routinely collected hospital admission data in England with dementia recorded in primary care.
Brown A; Kirichek O; Balkwill A; Reeves G; Beral V; Sudlow C; Gallacher J; Green J
Emerg Themes Epidemiol; 2016; 13():11. PubMed ID: 27800007
[TBL] [Abstract][Full Text] [Related]
17. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study.
Persson MSM; Harman KE; Vinogradova Y; Langan SM; Hippisley-Cox J; Thomas KS; Gran S
Br J Dermatol; 2021 Jan; 184(1):68-77. PubMed ID: 32147814
[TBL] [Abstract][Full Text] [Related]
18. Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.
Yu-Yang S; Chu-Sung Hu S; Yiao-Lin S
Acta Dermatovenerol Croat; 2017 Oct; 25(3):255-256. PubMed ID: 29252183
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study].
Morel P; Guillaume JC
Ann Dermatol Venereol; 1984; 111(10):925-8. PubMed ID: 6395773
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of Clinical Responses to Therapies in Infantile Bullous Pemphigoid.
Taquin H; Chiaverini C; Lacour JP
Pediatr Dermatol; 2016; 33(2):e77-81. PubMed ID: 26764161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
